Neonate intestinal immune response to CpG oligodeoxynucleotide stimulation

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Lacroix Lamandé, Sonia ^a   Rochereau, Nicolas ^a   Mancassola, Roselyne ^a   Barrier, Mathieu ^a   Clauzon, Amandine ^a   Laurent, Fabrice ^a  

^a UR1282   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; CHEMOKINE CXCL15; CHEMOKINE CXCL4; CHEMOKINE RECEPTOR CXCR3; CPG OLIGODEOXYNUCLEOTIDE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE LOCATION; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; MOUSE; NEWBORN; NONHUMAN; TH1 CELL; AGING; ANIMAL; C57BL MOUSE; CELL MOTION; CELL SEPARATION; CYTOLOGY; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; INFLAMMATION; INTESTINE; INTESTINE CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH NODE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RAT;

MUS;

ADMINISTRATION, ORAL; AGING; ANIMALS; ANIMALS, NEWBORN; CELL MOVEMENT; CELL SEPARATION; CHEMOKINES; ENTEROCYTES; FEMALE; IMMUNITY; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTESTINAL MUCOSA; INTESTINES; LYMPH NODES; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RATS; TH1 CELLS;

EID: 77949502920     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008291     Document Type: Article

References (28)

1. Wilson CB, Lewis DB, English BK (1991) T cell development in the fetus and neonate. Adv Exp Med Biol 310: 17-27.
2. Adkins B, Leclerc C, Marshall-Clarke S (2004) Neonatal adaptive immunity comes of age. Nat Rev Immunol 4: 553-564.
3. Marchant A, Goldman M (2005) T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol 141: 10-18.
4. Fadel SA, Ozaki DA, Sarzotti M (2002) Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. J Immunol 169: 3293-3300.
5. Ramirez K, Capozzo AV, Lloyd SA, Sztein MB, Nataro JP, et al. (2009) Mucosally delivered salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J Immunol 182: 1211-1222.
6. Czerkinsky C, Anjuere F, McGhee JR, George-Chandy A, Holmgren J, et al. (1999) Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 170: 197-222.
7. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
8. Kumagai Y, Takeuchi O, Akira S (2008) TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 60: 795-804.
9. Ballas ZK (2007) Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 39: 15-21.
10. Gupta K, Cooper C (2008) A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 9: 137-145.
11. Jahrsdorfer B, Weiner GJ (2008) CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 3: 27-32.
12. Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, et al. (2005) CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 174: 777-782.
13. Raghavan S, Nystrom J, Fredriksson M, Holmgren J, Harandi AM (2003) Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect Immun 71: 7014-7022.
14. Barrier M, Lacroix-Lamande S, Mancassola R, Auray G, Bernardet N, et al. (2006) Oral and intraperitoneal administration of phosphorothioate oligodeox- ynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice. J Infect Dis 193: 1400-1407.
15. Perreault N, Beaulieu JF (1998) Primary cultures of fully differentiated and pure human intestinal epithelial cells. Exp Cell Res 245: 34-42.
16. Bens M, Bogdanova A, Cluzeaud F, Miquerol L, Kerneis S, et al. (1996) Transimmortalized mouse intestinal cells (m-ICc12) that maintain a crypt phenotype. Am J Physiol 270: C1666-1674.
17. Auray G, Lacroix-Lamande S, Mancassola R, Dimier-Poisson I, Laurent F (2007) Involvement of intestinal epithelial cells in dendritic cell recruitment during C. parvum infection. Microbes Infect 9: 574-582.
18. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, et al. (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754.
19. Monteleone I, Platt AM, Jaensson E, Agace WW, Mowat AM (2008) IL-10- dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol 38: 1533-1547.
20. Siegrist CA (2007) The challenges of vaccine responses in early life: selected examples. J Comp Pathol 137 Suppl 1: S4-9.
21. Lacroix-Lamande S, Mancassola R, Naciri M, Laurent F (2002) Role of gamma interferon in chemokine expression in the ileum of mice and in a murine intestinal epithelial cell line after Cryptosporidium parvum infection. Infect Immun 70: 2090-2099.
22. Lotz M, Gutle D, Walther S, Menard S, Bogdan C, et al. (2006) Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med 203: 973-984.
23. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S (2005) Oral administration of second-generation immunomodulatory oligonucleotides in- duces mucosal Th1 immune responses and adjuvant activity. Vaccine 23: 2614-2622.
24. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, et al. (2006) Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 8: 1327-1336.
25. Lecce JG (1979) Intestinal barriers to water-soluble macromolecules. Environ Health Perspect 33: 57-60.
26. Shibolet O, Podolsky DK (2007) TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol 292: G1469-1473.
27. Tourais-Esteves I, Bernardet N, Lacroix-Lamande S, Ferret-Bernard S, Laurent F (2008) Neonatal goats display a stronger TH1-type cytokine response to TLR ligands than adults. Dev Comp Immunol 32: 1231-1241.
28. Booth JS, Griebel PJ, Babiuk LA, Mutwiri GK (2009) A novel regulatory B-cell population in sheep Peyer's patches spontaneously secretes IL-10 and downregulates TLR9-induced IFNalpha responses. Mucosal Immunol 2: 265-275.